Corporate$GILD8:53 AM ET

Gilead to present late-breaking HIV data at Glasgow conference

By BORSA NewsroomPublished Nov 2, 2026, 8:53 AM ESTUpdated Nov 2, 2026, 8:54 AM EST

Gilead Sciences announced it will present data from over 50 studies at HIV Glasgow 2026, including Phase 2 lenacapavir PrEP persistence, Phase 3 BIC/LEN (Bixlenvo) results, Phase 3 islatravir/lenacapavir weekly oral regimen, and Phase 1b amtabafusp alfa cure data. The conference runs Nov 8-11.

Sentimentneutral 50

Neutral · 50 of 100

Impact25

low · stays off the top drivers

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

Gilead will present at HIV Glasgow 2026, Nov 8-11